Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection

References

• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Nast A, Altenburg A, Augustin M, et al. German S3-guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 1: treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934–150.
   Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther (Heidelb). 2021;11(1):235–252.
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Ferrillo M, et al. QuantiFERON-TB gold conversion is not uncommon in patients with psoriasis undergoing anti-tumour necrosis factor-α therapy. Br J Dermatol. 2020;183(5):977–978.
   PubMed Web of Science ®Google Scholar
• Megna M, Ferrillo M, Ruggiero A, et al. QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study. Int J Dermatol. 2021;60(3):352–357.
   PubMed Web of Science ®Google Scholar
• Snast I, Bercovici E, Solomon-Cohen E, et al. Active tuberculosis in patients with psoriasis receiving biologic therapy: a systematic review. Am J Clin Dermatol. 2019;20(4):483–491.
   PubMed Web of Science ®Google Scholar
• Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016;15(10):1413–1420.
   PubMed Web of Science ®Google Scholar
• Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford). 2019;58(2):e3–e42.
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris – part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317.
   PubMed Web of Science ®Google Scholar
• Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628–637.
   PubMed Web of Science ®Google Scholar
• Sacchelli L, Magnano M, Loi C, et al. The unforeseen during biotechnological therapy for moderate-to-severe psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis, hepatitis B virus, hepatitis C virus, and HIV, surgery, vaccinations, diagnosis of malignancy, and dose tapering. Dermatol Ther. 2020;33(3):e13411.
   PubMed Web of Science ®Google Scholar
• Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503–509.
   PubMed Web of Science ®Google Scholar
• Daniel VT, Blankenship KC, Daly RF, et al. Low rate of conversion to positive tuberculosis status among patients with psoriasis on biologic therapies: a retrospective study from a US academic medical center. J Am Acad Dermatol. 2021;84(3):830–833.
   PubMed Web of Science ®Google Scholar
• Fowler E, Ghamrawi RI, Ghiam N, et al. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1449–1456.
   PubMed Web of Science ®Google Scholar
• Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis – time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35(4):824–834.
   PubMed Web of Science ®Google Scholar
• Wu CY, Chiu HY, Tsai TF. The seroconversion rate of QuantiFERON-TB Gold in-tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. PLoS One. 2019;14(12):e0225112.
   PubMed Web of Science ®Google Scholar
• Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond. Clin Chest Med. 2019;40(4):721–739.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.
   PubMed Web of Science ®Google Scholar
• Lambert JLW, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2). J Eur Acad Dermatol Venereol. 2020;34(9):1914–1923.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gladman DD, McInnes IB, et al. Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. J Rheumatol. 2020;47(4):539–547.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2015;16(4):323–330.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Coates LC, et al. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34(6):1161–1173.
   PubMed Web of Science ®Google Scholar
• Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.
   PubMed Web of Science ®Google Scholar
• Thaci D, Puig L, Reich K, et al. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: results from the CLEAR study. J Am Acad Dermatol. 2019;81(6):1405–1409.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017;56(11):1993–2003.
   PubMed Web of Science ®Google Scholar
• Ribero S, Licciardello M, Quaglino P, et al. Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol. 2019;11(Suppl 1):23–28.
   PubMedGoogle Scholar
• Fiorella C. Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: a multi-case report analysis. Clin Case Rep. 2022;10(1):e05302.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021;157(1):43–51.
   PubMed Web of Science ®Google Scholar
• Shu D, Zhang Z, Zhou EY, et al. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study. Dermatol Ther. 2020;33(6):e14512.
   PubMed Web of Science ®Google Scholar
• Machado A, Abreu M, Torres T. Safety of secukinumab in psoriasis patients with latent tuberculosis infection. Eur J Dermatol. 2020;30(6):740–741.
   PubMed Web of Science ®Google Scholar
• Kammuller M, Tsai TF, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunology. 2017;6(8):e152.
   PubMedGoogle Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–1514.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Deodhar A, McInnes IB, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: Update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022.DOI:10.2340/actadv.v102.563
   PubMed Web of Science ®Google Scholar
• Jagger A, Reiter-Karam S, Hamada Y, et al. National policies on the management of latent tuberculosis infection: review of 98 countries. Bull World Health Organ. 2018;96(3):173–184F.
   PubMed Web of Science ®Google Scholar
• Ai JW, Ruan QL, Liu QH, et al. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5:e10.
   PubMed Web of Science ®Google Scholar
• Haroon M, Martin U, Devlin J. High incidence of intolerance to tuberculosis chemoprophylaxis. Rheumatol Int. 2012;32(1):33–37.
   PubMed Web of Science ®Google Scholar